| VC-Backed Life Sciences Companies Get Fresh Cash The Burrill Report submits: By Marie DaghlianMay ended with a slew of venture-backed companies receiving fresh capital to move development of their products. Medtronic (MDT) made the biggest investment, putting $70 million into Israeli medical device company BioControl Medical. It was an unusual type of investment because the company’s previous investors opted for a direct investment with an option to acquire the company rather than a typical financing round.Complete Story » seekingalpha.com |
Antigenics: Bright Future Ahead VFC submits: Shares of Antigenics (AGEN) approached the one dollar mark during Tuesday's trading session after the company released a positive update regarding a Phase I trial for AG-707, a potential treatment for herpes simplex virus-2 (HSV-2), the virus that causes genital herpes. AG-707, if it works as advertised, is not a cure for the disease, but could help in treatment and prevention.Phase I results come too soon in a pipeline to get really excited about when looking at the short to mid term, but the early success of this product only adds to the potentially bright future of Antigenics. Complete Story » seekingalpha.com |
Axial Capital Adds to QLTI Position Again Market Folly submits:Eliav Assouline and Marc Andersen's hedge fund Axial Capital Management are at it again. They've purchased an additional 100,000 shares of QLT Inc (QLTI) at a price of $5.70. The purchase, which took place on August 11th, 2010, means that Assouline & Andersen's hedge fund now owns 6,441,812 QLTI shares. As we've extensively detailed, Axial has been buying QLTI over the course of a few months. Some investors have categorized QLT Inc as a value trap while others think of it as a 'cigarette-butt' value play. Essentially, many investors are betting on the biotech company's royalty stream. Those categorizing it as a value trap think that this royalty stream, while healthy now, is likely to decline. Andersen and Assouline obviously disagree with that take since they have been accumulating shares.Complete Story » seekingalpha.com |
Several Scenarios Ahead of the FDA's Imminent Decision on Alexza M.E. Garza submits: By Patrick CrutcherBiotech investors should be ready for a big week. With multiple FDA decisions on the line, there should be ample trading and investing opportunities out there. Let's focus on one of these events in particular.Complete Story » seekingalpha.com |
Biogen Idec: Earnings Preview Zacks.com submits: Biogen Idec Inc. (BIIB) is slated to announce its third quarter results on October 26. The Zacks Consensus Estimate is $1.20, well above the year-earlier earnings of $1.09. Second Quarter HighlightsComplete Story » seekingalpha.com |